What's the role of ibrutinib and venetoclax in CLL in light of data emerging from ASH 2022?
1
1 Answers
Mednet Member
Hematology · Mayo Clinic
Authored by @Dr. First Last and @Dr. First Last
The current FDA-approved, standard-of-care for frontline chronic lymphocytic leukemia (CLL) therapy includes continuous therapy with a Bruton tyrosine kinase inhibitor (BTKi) such as ibrutinib or acalabrutinib, with or without an anti-CD20 antibody, or...